Drugs / Amimestrocel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06954740 | Jun 2025 → Aug 2026 overdue | acute kidney injury | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06969807 | Jun 2025 → Aug 2026 overdue | diabetic kidney disease | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amimestrocel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06954740 ↗ |
| Modality | Cell therapy | “human umbilical cord mesenchymal stromal cells” NCT06954740 ↗ |
| Route | Intravenous | “Amimestrocel is administered via Intravenous infusion” NCT06954740 ↗ |